Lipid raft facilitated ligation of K-α1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation

Biochemical and Biophysical Research Communications

Volumn 399, Issue 2, 2010, Pages 251-255

  Tiriveedhi, Venkataswarup ^a   Angaswamy, Nataraju ^a   Weber, Joseph ^a   Mohanakumar, T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic rejection; K tubulin; Lipid rafts; Lung transplantation

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BETA METHYL CYCLODEXTRAN; DEXTRAN DERIVATIVE; K ALPHA1 TUBULIN; K ALPHA1 TUBULIN ANTIBODY; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID RAFT; LUNG ALVEOLUS EPITHELIUM; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES; BETA-CYCLODEXTRINS; BRONCHIOLITIS OBLITERANS; CELLS, CULTURED; CHRONIC DISEASE; FIBROBLAST GROWTH FACTOR 2; GRAFT REJECTION; HUMANS; LUNG TRANSPLANTATION; MEMBRANE MICRODOMAINS; PLATELET-DERIVED GROWTH FACTOR; RESPIRATORY MUCOSA; TUBULIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955844758     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.063     Document Type: Article

References (30)

1. Christie J.D., Edwards L.B., Aurora P., Dobbels F., Kirk R., Rahmel A.O., Taylor D.O., Kucheryavaya A.Y., Hertz M.I. Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J. Heart Lung Transplant. 2008, 27:957-969.
2. Burton C.M., Carlsen J., Mortensen J., Andersen C.B., Milman N., Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2007, 26:681-686.
3. Valentine V.G., Robbins R.C., Berry G.J., Patel H.R., Reichenspurner H., Reitz B.A., Theodore J. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J. Heart Lung Transplant. 1996, 15:371-383.
4. Al-Githmi I., Batawil N., Shigemura N., Hsin M., Lee T.W., He G.W., Yim A. Bronchiolitis obliterans following lung transplantation. Eur. J. Cardiothorac. Surg. 2006, 30:846-851.
5. Nath D.S., Basha H.I., Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr. Opin. Organ. Transplant. 2010, 15:16-20.
6. Burlingham W.J., Love R.B., Jankowska-Gan E., Haynes L.D., Xu Q., Bobadilla J.L., Meyer K.C., Hayney M.S., Braun R.K., Greenspan D.S., Gopalakrishnan B., Cai J., Brand D.D., Yoshida S., Cummings O.W., Wilkes D.S. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 2007, 117:3498-3506.
7. Goers T.A., Ramachandran S., Aloush A., Trulock E., Patterson G.A., Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J. Immunol. 2008, 180:4487-4494.
8. Tiriveedhi V., Weber J., Seetharam A., Mohanakumar T. Cross-talk of alloimmune response and autoimmunity: role in pathogenesis of chronic rejection. Discov. Med. 2010, 9:229-235.
9. Zissel G., Ernst M., Rabe K., Papadopoulos T., Magnussen H., Schlaak M., Muller-Quernheim J. Human alveolar epithelial cells type II are capable of regulating T-cell activity. J. Investig. Med. 2000, 48:66-75.
10. Jaramillo A., Smith C.R., Maruyama T., Zhang L., Patterson G.A., Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum. Immunol. 2003, 64:521-529.
11. Langenbach S.Y., Zheng L., McWilliams T., Levvey B., Orsida B., Bailey M., Williams T.J., Snell G.I. Airway vascular changes after lung transplant: potential contribution to the pathophysiology of bronchiolitis obliterans syndrome. J. Heart Lung Transplant. 2005, 24:1550-1556.
12. Aris R.M., Walsh S., Chalermskulrat W., Hathwar V., Neuringer I.P. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am. J. Respir. Crit. Care Med. 2002, 166:417-422.
13. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., Kintscher U., Rudolph B., Hoebeke J., Eckert D., Mazak I., Plehm R., Schonemann C., Unger T., Budde K., Neumayer H.H., Luft F.C., Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005, 352:558-569.
14. Dubel L., Farges O., Johanet C., Sebagh M., Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 1998, 65:1072-1075.
15. Levitan I., Christian A.E., Tulenko T.N., Rothblat G.H. Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells. J. Gen. Physiol. 2000, 115:405-416.
16. Christian A.E., Haynes M.P., Phillips M.C., Rothblat G.H. Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 1997, 38:2264-2272.
17. Zidovetzki R., Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence misconceptions and control strategies. Biochim. Biophys. Acta 2007, 1768:1311-1324.
18. Murata M., Peranen J., Schreiner R., Wieland F., Kurzchalia T.V., Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc. Natl. Acad. Sci. USA 1995, 92:10339-10343.
19. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
20. Levitan I., Gooch K.J. Lipid rafts in membrane-cytoskeleton interactions and control of cellular biomechanics: actions of oxLDL. Antioxid. Redox Signal 2007, 9:1519-1534.
21. Yin H.L., Janmey P.A. Phosphoinositide regulation of the actin cytoskeleton. Annu. Rev. Physiol. 2003, 65:761-789.
22. del Pozo M.A., Alderson N.B., Kiosses W.B., Chiang H.H., Anderson R.G., Schwartz M.A. Integrins regulate rac targeting by internalization of membrane domains. Science 2004, 303:839-842.
23. Miceli M.C., Moran M., Chung C.D., Patel V.P., Low T., Zinnanti W. Co-stimulation and counter-stimulation: lipid raft clustering controls TCR signaling and functional outcomes. Semin. Immunol. 2001, 13:115-128.
24. Gomez-Mouton C., Abad J.L., Mira E., Lacalle R.A., Gallardo E., Jimenez-Baranda S., Illa I., Bernad A., Manes S., Martinez A.C. Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. Proc. Natl. Acad. Sci. USA 2001, 98:9642-9647.
25. Rao S., Aberg F., Nieves E., Band Horwitz S., Orr G.A. Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry 2001, 40:2096-2103.
26. Dozier J.H., Hiser L., Davis J.A., Thomas N.S., Tucci M.A., Benghuzzi H.A., Frankfurter A., Correia J.J., Lobert S. Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res. 2003, 5:R157-169.
27. Hein S., Scheffold T., Schaper J. Ischemia induces early changes to cytoskeletal and contractile proteins in diseased human myocardium. J. Thorac. Cardiovasc. Surg. 1995, 110:89-98.
28. Krebs R., Tikkanen J.M., Nykanen A.I., Wood J., Jeltsch M., Yla-Herttuala S., Koskinen P.K., Lemstrom K.B. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am. J. Respir. Crit. Care Med. 2005, 171:1421-1429.
29. Dudez T., Borot F., Huang S., Kwak B.R., Bacchetta M., Ollero M., Stanton B.A., Chanson M. CFTR in a lipid raft-TNFR1 complex modulates gap junctional intercellular communication and IL-8 secretion. Biochim. Biophys. Acta 2008, 1783:779-788.
30. Simons K., Ehehalt R. Cholesterol, lipid rafts, and disease. J. Clin. Invest. 2002, 110:597-603.